甲基斑蝥胺抗乙型肝炎病毒体外实验研究

用２．２．１５细胞株体外抗ＨＢＶ药物模型，对研制的甲基斑蝥胺药物体外抗ＨＢＶ流行性进行评价。应用固相放射免疫测定法检测药物对２．２．１５细胞所分泌的ＨＢｓＡｇ、ＨＢｅＡｇ的抑制效果，应用Ｓｏｕｔｈｅｒｎ转膜杂交法分析药物对ＨＢＶ－ＤＮＡ的区带影响，同时以ＭＴＴ法检测药物细胞毒性。药物对病毒复制指标ＨＢｓＡｇ、ＨＢｅＡｇ的５０％抑制浓度（ＩＤ５０）分别为２．８３ｇ／Ｌ、４．６０ｇ／Ｌ，该药对ＨＢＶ－ＤＮＡ区带无明显影响，药物对细胞的５０％毒性浓度（ＣＤ５０）１０．６０ｇ／Ｌ。药物对ＨＢｓＡｇ、ＨＢｅＡｇ的治疗指数（ＴＩ）＝ＣＤ５０／ＩＤ５０分别为３．７５、２．３０。说明甲基斑蝥胺药物在体外具有一定抗ＨＢＶ活性。

INHIBITORY EFFECT OF METHYLCANTHARIDIMIDE ON HEPATITIS B VIRUS IN VITRO

Using an assay system based on 2.2.15 cell strain,methylcantharidimide produced by our hospital was studied for its inhibitory ability on hepatitis B virus replication in vitro.We detected the inhibitory effect of methylcantharidimide on HBsAg/HBeAg expression of 2.2.15cell strain by solid phase radioimmunoassay(RIA),and analysed the inhibitory effect of methylcantharidimide on HBV DNA by southern hybridisation,and detected the cell viability during the experiment by MTT.The results showed that the concentrations for 50% inhibition of HBsAg/HBeAg expression (ID50) were 2.83 g/L and 4.60 g/L;the inhibitory effect of methylcantharidimide on HBV DNA wasn′t noticeable,The concentration for 50% cell viability (CD50) was 10.60 g/L.The drug′s therapeutic indices (TI=CD50/ID50) for HBsAg/HBeAg were 3.75 and 2.30.Results suggest that methylcantharidimide has an inhibitory abitlity on hepatitis B virus replication in vitro.